Journal article icon

Journal article

Low-dose vs standard-dose alteplase for patients with acute ischemic stroke: secondary analysis of the ENCHANTED randomized clinical trial

Abstract:
Importance A lower dose of intravenous alteplase appears to be a safer treatment option than the standard dose, reducing the risk of symptomatic intracerebral hemorrhage. There is uncertainty, however, over how this effect translates into an overall clinical benefit for patients with acute ischemic stroke (AIS). Objective To assess whether older, Asian, or severely affected patients with AIS who are considered at high risk of thrombolysis may benefit more f... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


Robinson, TG More by this author
More by this author
Department:
Oxford, MSD, Obstetrics & Gynaecology
Expand authors...
National Health and Medical Research Council of Australia More from this funder
Stroke Association More from this funder
National Council for Scientific and Technological Development of Brazil More from this funder
Ministry for Health, Welfare and Family Affairs of the Republic of Korea More from this funder
Publisher:
American Medical Association Publisher's website
Journal:
JAMA Neurology Journal website
Volume:
74
Issue:
11
Pages:
1328-1335
Publication date:
2017-10-02
Acceptance date:
2017-06-18
DOI:
EISSN:
2168-6157
ISSN:
2168-6149
Pubs id:
pubs:708486
URN:
uri:3e004a73-2ac8-4fd0-b868-cb36bf2d0c1e
UUID:
uuid:3e004a73-2ac8-4fd0-b868-cb36bf2d0c1e
Local pid:
pubs:708486

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP